140 related articles for article (PubMed ID: 28694672)
1. Benefit of everolimus in treatment of an intrahepatic cholangiocarcinoma patient with a
Bian JL; Wang MM; Tong EJ; Sun J; Li M; Miao ZB; Li YL; Zhu BH; Xu JJ
World J Gastroenterol; 2017 Jun; 23(23):4311-4316. PubMed ID: 28694672
[TBL] [Abstract][Full Text] [Related]
2. Identification of a Novel EHBP1-MET Fusion in an Intrahepatic Cholangiocarcinoma Responding to Crizotinib.
Yu Y; Liu Q; Li W; Qu Y; Zhang Y; Liu T
Oncologist; 2020 Dec; 25(12):1005-1008. PubMed ID: 32897609
[TBL] [Abstract][Full Text] [Related]
3. Clinical response to adding pyrotinib to pembrolizumab and lenvatinib for HER2-positive advanced intrahepatic cholangiocarcinoma: a case report.
Zhang JW; Yang X; Pan B; Xu Y; Lu X; Zhao HT
World J Surg Oncol; 2023 Mar; 21(1):108. PubMed ID: 36973682
[TBL] [Abstract][Full Text] [Related]
4. Precision oncology for intrahepatic cholangiocarcinoma in clinical practice.
Tomczak A; Springfeld C; Dill MT; Chang DH; Kazdal D; Wagner U; Mehrabi A; Brockschmidt A; Luedde T; Naumann P; Stenzinger A; Schirmacher P; Longerich T
Br J Cancer; 2022 Nov; 127(9):1701-1708. PubMed ID: 35986087
[TBL] [Abstract][Full Text] [Related]
5. Significant response to transarterial chemoembolization combined with PD-1 inhibitor and apatinib for advanced intrahepatic cholangiocarcinoma: A case report and literature review.
Zhang H; Han C; Zheng X; Zhao W; Liu Y; Ye X
J Cancer Res Ther; 2023 Aug; 19(4):1055-1060. PubMed ID: 37675736
[TBL] [Abstract][Full Text] [Related]
6. The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations.
Feng Y; Zhao M; Wang L; Li L; Lei JH; Zhou J; Chen J; Wu Y; Miao K; Deng CX
Cell Death Dis; 2024 Jan; 15(1):34. PubMed ID: 38212325
[TBL] [Abstract][Full Text] [Related]
7. Quercetin Inhibits Intrahepatic Cholangiocarcinoma by Inducing Ferroptosis and Inhibiting Invasion via the NF-[Formula: see text]B Pathway.
Song Y; Zhang Z; Chai Q; Zheng H; Qi Y; Xia G; Yu Z; Yang R; Huang J; Li Y; Peng C; Jiang B; Liu S
Am J Chin Med; 2023; 51(3):701-721. PubMed ID: 36823098
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeted and systemic therapy for intrahepatic cholangiocarcinoma: a multi-disciplinary approach.
Merath K; Tiwari A; Parikh AA; Pawlik TM
Future Oncol; 2023 Dec; 19(39):2607-2621. PubMed ID: 38108100
[TBL] [Abstract][Full Text] [Related]
9. Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab.
Limousin W; Laurent-Puig P; Ziol M; Ganne-Carrié N; Nahon P; Ait-Omar A; Seror O; Sidali S; Campani C; Blanc P; Lermine A; Marisa L; Zucman-Rossi J; Nault JC
J Hepatol; 2023 Dec; 79(6):1450-1458. PubMed ID: 37647991
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic Cholangiocarcinoma with High Microsatellite Instability and Tumor Mutation Burden That Responded Significantly to Pembrolizumab but Perforated within a Short Period.
Yamazaki S; Kubota K; Shimizu A; Notake T; Umemura K; Kamachi A; Goto T; Tomida H; Yamashita N; Sato M; Kanno H; Soejima Y
Intern Med; 2024 Apr; 63(8):1105-1112. PubMed ID: 37779076
[TBL] [Abstract][Full Text] [Related]
11. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma.
Zeng TM; Pan YF; Yuan ZG; Chen DS; Song YJ; Gao Y
Front Immunol; 2022; 13():943066. PubMed ID: 36159865
[TBL] [Abstract][Full Text] [Related]
12. A case of unresectable intrahepatic cholangiocarcinoma with a germline BRCA1 mutation.
Yamashita Y; Ishii Y; Serikawa M; Okamoto W; Tsuboi T; Tatsukawa Y; Nakamura S; Hirano T; Ikemoto J; Oka S
Clin J Gastroenterol; 2023 Jun; 16(3):470-475. PubMed ID: 36806982
[TBL] [Abstract][Full Text] [Related]
13. Exploration of a screening model for intrahepatic cholangiocarcinoma patients prone to cuproptosis and mechanisms of the susceptibility of CD274-knockdown intrahepatic cholangiocarcinoma cells to cuproptosis.
Shen Z; Cai J; Tao L; Zheng J; Ye Z; Liu Y; Pan H; Wang Y; Xu J; Liang X
Cancer Gene Ther; 2023 Dec; 30(12):1663-1678. PubMed ID: 37828105
[TBL] [Abstract][Full Text] [Related]
14. A Novel Trojan Horse Nanotherapy Strategy Targeting the cPKM-STMN1/TGFB1 Axis for Effective Treatment of Intrahepatic Cholangiocarcinoma.
Chen ZW; Kang FP; Xie CK; Liao CY; Li G; Wu YD; Lin HY; Zhu SC; Hu JF; Lin CF; Huang Y; Tian YF; Huang L; Wang ZW; Chen S
Adv Sci (Weinh); 2023 Nov; 10(32):e2303814. PubMed ID: 37789644
[TBL] [Abstract][Full Text] [Related]
15. In Vivo Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma.
Younger NT; Wilson ML; Martinez Lyons A; Jarman EJ; Meynert AM; Grimes GR; Gournopanos K; Waddell SH; Tennant PA; Wilson DH; Guest RV; Wigmore SJ; Acosta JC; Kendall TJ; Taylor MS; Sproul D; Mill P; Boulter L
Cancer Res; 2022 Apr; 82(8):1548-1559. PubMed ID: 35074757
[TBL] [Abstract][Full Text] [Related]
16. Methyltransferase like 3 inhibition limits intrahepatic cholangiocarcinoma metabolic reprogramming and potentiates the efficacy of chemotherapy.
Gao J; Fang Y; Chen J; Tang Z; Tian M; Jiang X; Tao C; Huang R; Zhu G; Qu W; Wu X; Zhou J; Fan J; Liu W; Shi Y
Oncogene; 2023 Aug; 42(33):2507-2520. PubMed ID: 37420030
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of a new intrahepatic cholangiocarcinoma cell line, ICC-X3.
Xu H; Luo W; Zhao Z; Miao X; Chai C; Hu J; Tang H; Zhang H; Zhou W
Hum Cell; 2023 Mar; 36(2):854-865. PubMed ID: 36662372
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG
Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma.
Param NJ; Bramel ER; Sia D
Surg Pathol Clin; 2022 Sep; 15(3):529-539. PubMed ID: 36049834
[TBL] [Abstract][Full Text] [Related]
20. Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
Turpin A; Descarpentries C; Grégoire V; Farchi O; Cortot AB; Jamme P
Oncologist; 2023 Jan; 28(1):80-83. PubMed ID: 36434677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
